

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**


Partial translation of JP-A-8-169884

Translation of Claims and paragraphs [0001] to [0004]:

[Claims]

[Claim 1] A cyclopropachromenecarboxylic acid derivative represented by the following general formula (1)

[Chem. 1]



[wherein A represents oxygen atom, hydroxyimino group, an alkyloxyimino group having from 1 to 5 carbon atoms or a group  $=N-O-(CH_2)_n-NR^1R^2$  (wherein n is an integer of from 2 to 8 and each of  $R^1$  and  $R^2$  independently represents hydrogen atom or an alkyl group having from 1 to 5 carbon atoms), B represents a group  $-COOR^3$  (wherein  $R^3$  represents hydrogen atom or an alkyl group having from 1 to 5 carbon atoms) or a group  $-CONR^4R^5$  (wherein each of  $R^4$  and  $R^5$  independently represents hydrogen atom, an alkyl group having from 1 to 5 carbon atoms, an alkenyl group having from 2 to 5 carbon atoms, an aminoalkyl group in which the N may be substituted, phenyl group substituted with a

halogen atom or hydroxyl group which may be substituted, 2-pyridyl group or an aralkyl group having from 7 to 10 carbon atoms, or  $\text{NR}^4\text{R}^5$  may together form a nitrogen-containing heterocyclic group which may be substituted), and X represents a halogen atom or a group  $-\text{OR}^6$  (wherein  $\text{R}^6$  represents hydrogen atom, an alkyl group having from 1 to 5 carbon atoms, an alkenyl group having from 3 to 6 carbon atoms or an aralkyl group having from 7 to 10 carbon atoms)] or a pharmacologically acceptable salt thereof.

[Claim 2] A therapeutic agent for various diseases caused by functional and/or organic disorders in the brain, which comprises a cyclopropachromenecarboxylic acid derivative represented by the general formula (1) of claim 1 or a pharmacologically acceptable salt thereof as the active ingredient.

[Detailed Description of the Invention]

[0001]

[Technical Field to which the Invention Belongs] This invention relates to novel cyclopropachromenecarboxylic acid derivatives and pharmacologically acceptable salts thereof. More particularly, it relates to novel cyclopropachromenecarboxylic acid derivatives and pharmacologically acceptable salts thereof, which have metabotropic glutamate receptor antagonism and are effective in improving and treating various diseases caused by functional and organic disorders in the brain, including

various symptoms caused by cerebral ischemic disorders such as aftereffects after cerebral infarction, after cerebral bleeding and after cerebral arteriosclerosis and other symptoms caused by various organic disorders induced by senile dementia, post-traumatic syndrome after head injury, secondary disease after brain operation, Alzheimer disease and Parkinson disease.

[0002]

[Prior Art] It is considered that abnormal activation of glutamate receptors caused by the excessive release of glutamic acid as an excitatory neurotransmitter in the living body is concerned in the progressive delayed neuronal cell death which is observed after brain injuries accompanied by head injuries and cerebrovascular diseases (cerebral bleeding, transient cerebral ischemia, cerebral infarction) [D.T. Monaghan et al., *Annu. Rev. Pharmacol. Toxicol.*, 29, 365 (1989); B. Meldrum et al., *Trends Pharmacol. Sci.*, 11, 379 (1990)]. Glutamate receptors are roughly classified into two types of ionotropic receptor (iGluR) which by itself has an ion channel function and a metabotropic receptor (mGluR) which communicates to intracellular signal transduction system via G protein [S. Nakanishi, *Science*, 258, 597 (1992)], and their antagonists have been researched and developed as drugs capable of preventing or inhibiting neuronal cell death. However, most of them are iGluR antagonists [J.C. Watkins et al.,

*Trends Pharmacol. Sci.*, 11, 15 (1990); D. Lodge et al., *ibid.*, 11, 81 (1990)], and only L-AP3 [D. Schoepp et al., *Trends Pharmacol. Sci.*, 14, 13 (1993)] and a phenylglycine derivative [Y. Hayashi et al., *J. Neurosci.*, 14, 3370 (1994)] are known as mGluR antagonists whose concern in neuronal cell death has recently been suggested [D. Bleakman et al., *Mol. Pharmacol.*, 42, 192 (1992); J.W. McDonald et al., *J. Neurosci.*, 13, 4445 (1993)].

[0003]

[Problems that the Invention is to Solve] Under the above background, the problem to be solved by the invention is to provide a novel compound which has mGluR antagonism and is useful as a drug for improving or treating functional and organic disorders in the brain.

[0004]

[Means for Solving the Problems] The present inventors have previously found that a cyclopropachromene derivative shows a brain protecting action under a reduced pressure low oxygen condition and have applied the result for a patent (JP-A-4-235180; the term "JP-A" as used herein means an "unexamined published Japanese patent application"). Thereafter, paying attention to mGluR, particularly to its subtype mGluR1 conjugated with hydrolysis of inositol phospholipid [M. Masu et al., *Nature*, 349, 760 (1991)] and using rat mGluR1 expressing CHO cells [S. Nakanishi et al., *Neuron*, 8, 757 (1992)], the inventors have conducted

extensive synthesis studies using, as an index, an antagonism for intracellular calcium ion increase induced by glutamic acid and found that a carboxylic acid derivative of cyclopropachromene has mGluR1 antagonism, thereby resulting in the accomplishment of the invention. Thus, the present invention provides, as a substance having mGluR1 antagonism, the following general formula (1)

Translation of paragraphs [0098] to [0101]:

[0098]

Evaluation Example 1. Evaluation of mGluR1 antagonism using intracellular  $\text{Ca}^{2+}$  response of mGluR1 expressing CHO cells as an index

Since mGluR1 (metabotropic glutamate receptor 1) induces release of  $\text{Ca}^{2+}$  from the intracellular  $\text{Ca}^{2+}$  storing region as an intracellular signal transduction system via the production of inositol 1,4,5-triphosphate, the mGluR1 antagonism can be evaluated using intracellular  $\text{Ca}^{2+}$  response in mGluR1-expressed cells as the index.

[0099]

By employing this evaluation system and using rat mGluR1-expressed CHO cells [S. Nakanishi et al., *Neuron*, 8, 757 (1992)], the amount of intracellular  $\text{Ca}^{2+}$  induced by 10  $\mu\text{M}$  of glutamic acid when compounds of the invention were

added in various concentrations was measured by a Fura-2-  
employed fluorometry [H. Sugino et al., *Brain Res.*, 322,  
127 (1984)], and the results were compared with the case of  
no addition of the test samples to evaluate antagonism of  
the compounds of the invention for mGluR1 using antagonism  
for the increase of intracellular  $\text{Ca}^{2+}$  as the index. As a  
result, all of the compounds of the invention showed  
antagonism for mGluR1, and as shown in Table 3, the  
compounds of Example Nos. 32, 34, 35, 36, 41, 42, 43 and 53  
showed particularly strong antagonism with a 50%  
competitive inhibition concentration (to be referred to as  
 $\text{IC}_{50}$ ) of 100  $\mu\text{M}$  or less. The  $\text{IC}_{50}$  values of (S)-4CPG and  
MCPG [Y. Hayashi et al., *J. Neurosci.*, 14, 3370 (1994)]  
used as control drugs were also shown in the table.

[0100]      Table 3

Example No.	$\text{IC}_{50}$ ( $\mu\text{M}$ )
32	23
34	20
35	3
36	10
41	100
42	100
43	20
53	100
(S)-4CPG	200
MCPG	700

[Effects of the Invention]

[0101]

According to the invention, novel carboxylic acid derivatives of cyclopropachromene and pharmacologically acceptable salts thereof having antagonism for metabotropic glutamate receptor can be provided. Since the compounds of the invention have antagonism for metabotropic glutamate receptor and also have low toxicity, their application is expected as medicaments for improving various diseases caused by functional disorders and organic disorders in the brain.